🇺🇸 FDA
Patent

US 8716301

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

granted A61KA61K2039/55561A61K31/00

Quick answer

US patent 8716301 (Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/55561, A61K31/00, A61K31/365, A61K31/519